Brief: Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis
16/01/2025 13:32
Jan 16 (Reuters) - Palisade Bio Inc PALI.O :
* PALISADE BIO COMPLETES ALL FIVE SAD COHORTS AND ADVANCES
TO MAD
COHORTS OF PHASE 1A/B STUDY OF PALI-2108 FOR TREATMENT OF
ULCERATIVE COLITIS
Source text: ID:nGNX4WyTLw
Further company coverage: PALI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palisade Bio
See all newsPalisade Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Palisade Bio Q2 net loss widens on higher R&D costs
Brief: Palisade Bio Q2 EPS USD -0.05
Palisade Bio Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Palisade Bio Inc - May Offer And Sell Up To $300 Million Of Securities - SEC Filing